Prostate cancer is one of the prominent death cause in males with alarming rates of inclusion
of new cases each year. There are many new classes of anti-tumor agents already investigated
that modulate the epigenetic or non-epigenetic mechanisms such as cell cycle arrest, apoptosis, cell
death within cancer cells. Histone deacetylase (HDAC) inhibitors are one of them. In recent times,
the use of HADC inhibitors are approved as a clinical molecule to treat a group of malignancies. Vorinostat
and depsipeptide are two new HDAC inhibitors that are approved by the Food and Drug
Administration. The present review is an effort to summarize the recent findings related to HDAC
inhibitors against prostate cancer along with their molecular mechanism and biological mode of actions
behind the anticancer efficacy.
Keywords: Classification, histone deacetylase, prostate cancer, recent advances, mammalian cells, DNA.
Rights & PermissionsPrintExport